KCNJ5变异致儿童库欣综合征及低剂量酮康唑治疗成功
本文报告一名10岁儿童因双侧肾上腺皮质增生(BAH)在早年出现库欣综合征(CS),全外显子测序发现其携带来自父亲的KCNJ5新发致病性变异(c.506T>C,p.L169S),低剂量酮康唑可控制高皮质醇血症及CS相关体征,停药6周即复发。体外研究显示该变异影响Kir3.4通道电导而不影响其表达或膜定位,对类固醇生成无影响,但蛋白激酶A活性有轻度改变。
要点
- 儿童双侧肾上腺皮质增生所致CS需考虑KCNJ5胚系变异可能
- 低剂量酮康唑可控制该患儿高皮质醇血症及CS体征
- 该KCNJ5变异功能不同于导致原发性醛固酮增多症的KCNJ5缺陷
核心结论
- 本文报告一例因双侧肾上腺皮质增生(BAH)导致库欣综合征(CS)的儿童患者,携带KCNJ5胚系变异(c.506T>C,p.L169S)。
- 该KCNJ5变异的功能不同于导致原发性醛固酮增多症(PA)的KCNJ5缺陷,分子研究未能明确其导致CS的原因。
- 作者推测GIRK4(Kir3.4)可能参与人类早期肾上腺皮质发育与分区,并参与儿童BAH的发病。
研究设计与样本
- 病例报告:一名10岁儿童,因双侧肾上腺皮质增生(BAH)在早年出现库欣综合征(CS)。
- 对已知导致皮质醇 producing BAH 的基因(PRKAR1A、PRKACA、PRKACB、PDE11A、PDE8B、ARMC5)进行筛查,未发现基因缺陷。
- 全外显子测序发现KCNJ5新发致病性变异(c.506T>C,p.L169S),遗传自父亲。
- 进行体外研究评估该变异对Kir3.4通道电导、表达、膜定位、类固醇生成及蛋白激酶A活性的影响,并进行计算机模拟分析。
主要发现
- 患儿接受低剂量酮康唑(KZL)治疗,高皮质醇血症及CS相关体征得到控制。
- 停用KZL仅6周即导致CS复发。
- 已知导致皮质醇 producing BAH 的基因筛查未发现缺陷。
- 全外显子测序显示KCNJ5新发致病性变异(c.506T>C,p.L169S),遗传自父亲。
- 体外研究显示p.L169S变异影响Kir3.4通道电导,但不影响其表达或膜定位;对类固醇生成无影响,但蛋白激酶A活性有轻度改变。
关键数值与推荐
- 低剂量酮康唑(KZL)可控制该患儿的高皮质醇血症及CS相关体征,停药6周即复发。
- KCNJ5变异为c.506T>C,p.L169S,遗传自父亲。
- 体外研究显示该变异影响Kir3.4通道电导,不影响表达或膜定位,对类固醇生成无影响,蛋白激酶A活性有轻度改变。
临床怎么用
- 对儿童双侧肾上腺皮质增生所致库欣综合征,可考虑筛查KCNJ5胚系变异。
- 低剂量酮康唑可作为控制该患儿高皮质醇血症及CS体征的治疗选择,但停药后可能复发。
- KCNJ5变异所致CS的机制可能不同于PA,需进一步研究以指导临床管理。
局限性
- 本文为单例病例报告,结论外推受限。
- 分子研究未能明确该KCNJ5变异导致CS的确切机制。
- 体外研究未显示该变异对类固醇生成的影响,其致病机制仍为推测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pathogenic variants in KCNJ5, encoding the GIRK4 (Kir3.4) potassium channel, have been implicated in the pathogenesis of familial hyperaldosteronism type-III (FH-III) and sporadic primary aldosteronism (PA). In addition to aldosterone, glucocorticoids are often found elevated in PA in association with KCNJ5 pathogenic variants, albeit at subclinical levels. However, to date no GIRK4 defects have been linked to Cushing syndrome (CS). PATIENT: We present the case of a 10-year-old child who presented with CS at an early age due to bilateral adrenocortical hyperplasia (BAH). The patient was placed on low-dose ketoconazole (KZL), which controlled hypercortisolemia and CS-related signs. Discontinuation of KZL for even 6 weeks led to recurrent CS. RESULTS: Screening for known genes causing cortisol-producing BAHs (PRKAR1A, PRKACA, PRKACB, PDE11A, PDE8B, ARMC5) failed to identify any gene defects. Whole-exome sequencing showed a novel KCNJ5 pathogenic variant (c.506T>C, p.L169S) inherited from her father. In vitro studies showed that the p.L169S variant affects conductance of the Kir3.4 channel without affecting its expression or membrane localization. Although there were no effects on steroidogenesis in vitro, there were modest changes in protein kinase A activity. In silico analysis of the mutant channel proposed mechanisms for the altered conductance. CONCLUSION: We present a pediatric patient with CS due to BAH and a germline defect in KCNJ5. Molecular investigations of this KCNJ5 variant failed to show a definite cause of her CS. However, this KCNJ5 variant differed in its function from KCNJ5 defects leading to PA. We speculate that GIRK4 (Kir3.4) may play a role in early human adrenocortical development and zonation and participate in the pathogenesis of pediatric BAH.
引用
- Tatsi C, Maria AG, Malloy C, et al. Cushing Syndrome in a Pediatric Patient With a KCNJ5 Variant and Successful Treatment With Low-dose Ketoconazole. J Clin Endocrinol Metab. 2021. PMID: 33630995. doi:10.1210/clinem/dgab118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。